Skip to Main Content


Yale Gynecologic Pathologists Are Pioneers in Clinical Validation and Application of Molecular Genotyping for Gestational Trophoblastic Disease

February 07, 2022

Yale Pathology’s experienced gynecological pathologists are pioneers in the clinical validation and application of molecular genotyping for gestational trophoblastic disease (GTD).

The expert consultants at Yale Gynecologic Pathology – including Pei Hui, MD, PhD, and Natalia Buza, MD – recently optimized an algorithm in the precise classification of molar gestations and gestational trophoblastic tumors.

GTD is a major disease category in gynecologic pathology, and morphologic assessment of hydatidiform moles – the most common GTD – continues to suffer from significant diagnostic and inter- and intra-observer variability, even among experienced pathologists. And yet, distinction of hydatidiform moles from non-molar specimens and subclassification of the moles is critical for patient care.

“Precise diagnosis of gestational trophoblastic disease, such as hydatidiform moles, is very important for patients as the clinical outcome and follow-up medical intervention can be drastically different depending on the types of the mole or trophoblastic tumor,” Dr. Hui said. “Yale Pathology consultants are internationally renowned experts who have pioneered the field of integrating molecular technology into the routine diagnosis of gestational trophoblastic disease.”

One of the best diagnostic measures to precisely classify hydatidiform moles to emerge in the past decade are p57 immunohistochemistry and PCR-based genotyping. The modern diagnostic approach requires integration of these ancillary techniques into the algorithm, recently optimized at Yale Gynecologic Pathology, that aims to provide a refined diagnosis and accurate risk assessment – and guide appropriate clinical management.

To learn more, contact Stephanie Weirsman at Yale Pathology Labs.

Submitted by Terence P. Corcoran on February 07, 2022